StockMarketWire.com - Collagen Solutions said it had formed an agreement with Olaregen Therapeutix to produce a treatment for hard-to-heal wounds such as diabetic foot ulcers.

The company said it would support the launch of Olaregen's launch of its so-called Excellagen product in the first half of 2019.

'This new agreement is consistent with our strategy to move up the value chain by collaborating with industry partners to develop and launch innovative products designed to improve patients' lives,' chief executive Jamal Rushdy said.


At 2:25pm: [LON:COS] Collagen Solutions Plc share price was +0.2p at 3.85p



Story provided by StockMarketWire.com